Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials

Acta Oncologica

Volumn 50, Issue 7, 2011, Pages 1006-1014

  Hoff, Camilla Molich ^a   Lassen, Pernille ^a   Eriksen, Jesper Grau ^a,c   Hansen, Hanne Sand ^b   Specht, Lena ^b   Overgaard, Marie ^a   Grau, Cai ^a   Johansen, Jørgen ^c   Bentzen, Jens ^d   Andersen, Lisbeth ^e   Evensen, Jan F ^f   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NIMORAZOLE; PLACEBO;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISTANT METASTASIS; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HAZARD RATIO; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NIMORAZOLE; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 80052891330     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.592650     Document Type: Article

References (40)

1. Hoff CM, Hansen HS, Overgaard M, Grau C, Johansen J, Bentzen J, et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiother Oncol 2011;98:28-33.
2. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40. (Pubitemid 37159288)
3. Overgaard J, Hansen HS, Jorgensen K, Hjelm HM. Primary radiotherapy of larynx and pharynx carcinoma - an analysis of some factors infl uencing local control and survival. Int J Radiat Oncol Biol Phys 1986;12:515-21. (Pubitemid 16081611)
4. Overgaard J. Sensitization of hypoxic tumour cells - clinical experience. Int J Radiat Biol 1989;56:801-11. (Pubitemid 20002032)
5. Grau C, Overgaard J. Signifi cance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P, editors. Blood perfusion and microenvironment of human tumors, implications for clinical radiooncology. Berlin: Springer; 1998. p. 101 - 12.
6. Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 2004;43:396-403. (Pubitemid 38887861)
7. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77: 18-24. (Pubitemid 41503384)
8. Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, et al. Infl uence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-54. (Pubitemid 29284123)
9. Evans JC, Bergsjo P. The infl uence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology 1965; 84:709-17.
10. Vaupel P, Mayer A, Hockel M. Impact of hemoglobin levels on tumor oxygenation: The higher, the better? Strahlenther Onkol 2006;182:63-71. (Pubitemid 43177190)
11. Horsman MR. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;42:701-4. (Pubitemid 28559401)
12. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007;25:4066-74. (Pubitemid 47492951)
13. H irst DG, Wood PJ. The adaptive response of mouse tumours to anaemia and retransfusion. Int J Radiat Biol Relat Stud Phys Chem Med 1987;51:597-609. (Pubitemid 17081455)
14. Hill RP, Bush RS, Yeung P. The effect of anaemia on the fraction of hypoxic cells in an experimental tumour. Br J Radiol 1971;44:299-304.
15. Hewitt HB, Blake ER. Effect of induced host anaemia on the viability and radiosensitivity of murine malignant cells in vivo. Br J Cancer 1971;25:323-36.
16. Hirst DG, Brown JM. The infl uence of hemoglobin level on radiobiological hypoxia in tumors. Adv Exp Med Biol 1986; 200:603-8.
17. Sealy R, Jacobs P, Wood L, Levin W, Barry L, Boniaszczuk J, et al. The treatment of tumors by the induction of anemia and irradiation in hyperbaric oxygen. Cancer 1989;64: 646-52. (Pubitemid 19185214)
18. Levine EA, Vijayakumar S. Blood transfusion in patients receiving radical radiotherapy: A reappraisal. Onkologie 1993;16:79-87. (Pubitemid 23221181)
19. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85 - 27. Int J Radiat Oncol Biol Phys 1998;42: 1069-75. (Pubitemid 29004150)
20. Dische S, Anderson PJ, Sealy R, Watson ER. Carcinoma of the cervix - anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 1983;56:251-5. (Pubitemid 13119078)
21. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63: 25-36. (Pubitemid 41583539)
22. Fortin A, Wang CS, Vigneault E. Effect of pretreatment anemia on treatment outcome of concurrent radiochemotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2008;72:255-60.
23. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Defi nitive evidence for hypoxic cells infl uencing cure in cancer therapy. Br J Cancer Suppl 1978;3: 302-6.
24. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP. Anemia, hypoxia and transfusion in patients with cervix cancer: A review. Radiother Oncol 2000;57:13-9.
25. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86: 1528-36. (Pubitemid 29489787)
26. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60. (Pubitemid 37324251)
27. Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007;69:1008-17. (Pubitemid 47625834)
28. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009;27:5751-6.
29. Barbera L, Thomas G. Erythropoiesis stimulating agents, thrombosis and cancer. Radiother Oncol 2010;95: 269-76.
30. Overgaard J, Hoff CM, Hansen HS, Specht L, Overgaard M, Grau C, et al. Randomized study of darbepoetin alfa as modifi er of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial. J Clin Oncol 2009;27: 15s Abstract 6007.
31. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373: 1532-42.
32. Lambin P, Ramaekers BL, van Mastrigt GA, Van den Ende P, de JJ, De Ruysscher DK, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009; CD006158.
33. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46:135-46. (Pubitemid 28109172)
34. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6: 757-64.
35. Eriksen JG, Steiniche T, Overgaard J. The infl uence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 2005;74:93-100. (Pubitemid 40331865)
36. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992 - 8.
37. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95:371-80.
38. Boeje CR, Dalton SO, Kristensen CA, Andersen E, Johansen J, Andersen LJ, et al. Comorbidity among 13651 head and neck cancer patients from the DAHANCAdatabase. Radiother Oncol 2011;98:S1,3.
39. Blajchman MA, Bordin JO. The tumor growth-promoting effect of allogeneic blood transfusions. Immunol Invest 1995; 24:311-7.
40. Bentzen SM, Balslev I, Pedersen M, Teglbjaerg PS, Hanberg- Sorensen F, Bone J, et al. Blood transfusion and prognosis in Dukes ' B and C colorectal cancer. Eur J Cancer 1990;26: 457-63. (Pubitemid 20209975)